Advancing Healthcare Through Personalized Medicine

2. Auflage 2021
ISBN: 978-3-030-80099-4
Verlag: Springer International Publishing

Buch, Englisch, 745 Seiten, HC gerader Rücken kaschiert, Format (B × H): 160 mm x 241 mm, Gewicht: 1448 g

This book provides a unique perspective on the biomedical and societal implications of personalized medicine and how it helps to mitigate the healthcare crisis and rein in ever-growing expenditure. It introduces the reader to the underlying concepts at the heart of personalized medicine. 

An innovative second edition, this book functions as an update to the successful first edition to include new, state-of-the-art information and advancements in the fast-paced field of personalized medicine.

Chapters examine pharmacogenomics, targeted therapies, individualized diagnosis and treatment, and cancer immunotherapies. The book also features an essential discussion on how the advent of genomic technologies gives clinicians the capability to predict and diagnose disease more efficiently and offers a detailed up-to-date compilation of clinical trials in cancer leading to breakthrough therapies. The book also addresses the impact of Big Data on personalized medicine and the newfound applications of digital health and artificial intelligence. 

A work that advocates for a patient-centered approach, Advancing Healthcare Through Personalized Medicine, Second Edition is an invaluable text for clinicians, healthcare providers, and patients.

Zielgruppe

Professional/practitioner

Autoren/Hrsg.

Hays, Priya

Fachgebiete

• Medizin | Veterinärmedizin Medizin | Public Health | Pharmazie | Zahnmedizin Klinische und Innere Medizin Innere Medizin

Inhaltsverzeichnis

1. Introduction: Biomedical Innovation and Policy in the Twenty-First Century.- 2. The Rise of Genomics and Personalized Medicine.- 3. Patient Narratives: Personalized Medicine in the Field.- 4. Alliances: Knowledge Infrastructures, and the Digitization of Precision Health.- 5. Tumor Genesis and Precision Oncology.- 6. Trends in Precision Oncology and Precision Medicine 2.0.- 7.Personalized medicine’s impact on disease.- 8. The Genome in the Clinic and Boardroom: Biomarkers, Diagnosis, Treatment, and Education.- 9. A New Set of Clinical tools for Physicians.- 10. Legislation, Reimbursement and the Regulatory Landscape.- 11. Translational personalized medicine: Molecular profiling, druggable targets, and clinical genomic medicine.- 12. The Health Economics of Personalized Precision Medicine.- 13. Moral, Societal and Ethical Issues: Claims, Consequences, and Caveats.- 14. Conclusion.

Über Autor(innen)

Priya Hays

Hays Documentation Specialists, LLC

San Mateo

California

USA

Priya Hays, Ph.D. is an accomplished science writer, having written and published four books as well as having authored over twenty publications in journals as varied as the Bulletin of Science, Technology and Society, L’Esprit Createur, Interdisciplinary Literary Studies, Genetics in Medicine, Journal of Clinical Investigation and Studies, and Preventive Medicine, Epidemiology and Public Health. The publication of the first edition of Advancing Healthcare Through Personalized Medicine brought Dr. Hays much prominence and credibility in the personalized and genomic medicine field. She was elected to three prestigious medical societies (as Allied Physician/Doctoral Scientist of the American Society of Clinical Oncology; as Affiliate Member of the American College of Medical Genetics and Genomics; and as Memberof the Society for Immunotherapy of Cancer). Additionally, she has published an editorial on personalized medicine in the journal Genetics in Medicine and a paper in collaboration with two physicians at the University of California, San Diego Health System on clinical care of patients taking immunotherapies and managing their adverse effects in the journal Future Oncology. She is also serving as Guest Editor for an upcoming volume on cancer immunotherapies in the Cancer Treatment and Research series.  She completed her postdoctoral research fellowship in the Division of Hematology/Oncology, Department of Medicine, at Dartmouth Medical School. She has an A.B. with Honors from Dartmouth College in Biochemistry and Comparative Literature, an M.S. in Genetics from the University of California, Davis, and a Ph.D. in Literature from the University of California, San Diego.